ライフサイエンスコーパス: third trimester

1 nd trimester, and 29% after infection in the third trimester).

2 ne patients had a caesarean section in their third trimester.

3 regnancy, which peaked in the middle to late third trimester.

4 in the second trimester, and 2 (8.3%) in the third trimester.

5 r Tdap was administered during the second or third trimester.

6 well as maternal blood FT4 concentrations at third trimester.

7 in the second trimester, and 5.1E-03 in the third trimester.

8 e sizes and measured the exposure during the third trimester.

9 verall, decreasing further at the end of the third trimester.

10 vitamin B-12 decrease from the first to the third trimester.

11 tal brain injury acquired due to ZIKV in the third trimester.

12 ter, 4 in the second trimester, and 1 in the third trimester.

13 ation of all pregnant women in the second or third trimester.

14 en, with the lowest risk reported during the third trimester.

15 trimester and to syncytiotrophoblasts in the third trimester.

16 s pregnancy progresses from the first to the third trimester.

17 pling, and with lower levels of HDL-C in the third trimester.

18 n newborns exposed to natalizumab during the third trimester.

19 2 y old and 20.9% of pregnant women in their third trimester.

20 ester (29.2%) and much higher (95.3%) in the third trimester.

21 as well as lower levels of HDL-C during the third trimester.

22 methods in these patients, especially in the third trimester.

23 cond trimesters of pregnancy compared to the third trimester.

24 ance index and fetal growth were measured in third trimester.

25 74 g less (95% CI, -140 to -8 g) during the third trimester.

26 ompared to women screened and treated in the third trimester.

27 ts on lung epithelial cell maturation in the third trimester.

28 duled antenatal care visit in the second and third trimester.

29 ed with efavirenz, when initiated during the third trimester.

30 (49/60) reported onset during the second or third trimester.

31 acid were significantly higher in SCH in the third trimester.

32 tion of at least 28 weeks, initiating ART in third trimester.

33 mester and in 32% who began the study in the third trimester.

34 arriers inside the cortical plate during the third trimester.

35 962 mothers were vaccinated in the second or third trimesters.

36 with underlying conditions, and 67% in their third trimesters.

37 formations but is feasible in the second and third trimesters.

38 r and greater than 3 mIU/L in the second and third trimesters.

39 gastric bypass surgery during the second and third trimesters.

40 ance indices were assessed in the second and third trimesters.

41 ine sample in each of the first, second, and third trimesters.

42 o Zika virus infection only in the second or third trimesters.

43 concentrations are measured in the second or third trimesters.

44 ricity index decreased from the first to the third trimester (1.92+/-0.17 versus 1.71+/-0.17) and ret

45 loma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% in the second

46 in those with an onset during the second or third trimester (3% vs. 1%).

47 Serial first- (11-14 weeks) and third-trimester (30-34 weeks) serum samples were analyze

48 clampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied.

49 , and having the first prenatal visit in the third trimester (33.3% vs. 14.3% and 10.5% in the second

50 e or four scheduled visits in the second and third trimester, 4 to 6 wk apart.

51 antly associated with maternal anemia in the third trimester (adjusted odds ratio 2.25, 95% confidenc

52 harmacokinetic profiles performed during the third trimester and >/=2 weeks after delivery.

53 al diabetes mellitus who were exposed in the third trimester and 1.02 (95% confidence interval: 1.01,

54 oad declines of at least 1 log10 between the third trimester and 3-mo postpartum exhibited HCV-specif

55 aemoglobin concentration measured during the third trimester and after delivery.

56 Maternal RSV antibody titers in the third trimester and at birth were strongly correlated (R

57 We screened pregnant women in their second/third trimester and at delivery for LTBI using the tuber

58 harmacokinetic sampling was performed in the third trimester and at least 2 weeks postpartum.

59 hers received acellular pertussis during the third trimester and children aged 2 months to 11 years w

60 Mothers during the third trimester and children at ages 3, 5, and 7 years p

61 nce maternal-infant attachment, began in the third trimester and continued until 6 mo postpartum.

62 A and PC:PE ratios, in pregnant women in the third trimester and nonpregnant women.

63 harmacokinetic profiles were obtained in the third trimester and postpartum along with cord and mater

64 rine samples collected during the second and third trimesters and examined temporal trends of metabol

65 .0 g for exposures in the first, second, and third trimesters and for the total pregnancy, respective

66 .4 g for exposures in the first, second, and third trimesters and for the total pregnancy, respective

67 acental resistance indices in the second and third trimesters and persistence in the highest tertile

68 ed from pregnant women during the second and third trimesters and their children at 1 and 2 years of

69 ant concentrations in the first, second, and third trimesters and throughout the entire pregnancy.

70 arbon monoxide during the first, second, and third trimesters and total pregnancy were 1.005 (95% CI:

71 nal plasma samples pooled from the first and third trimesters and urine samples from children at age

72 Third-trimester and childhood BC exposures were associat

73 e-time survival models were used to estimate third-trimester and total pregnancy associations.

74 ases of botulism during pregnancy (11 in the third trimester) and 1 case during the postpartum period

75 Pregnant women (second or third trimester) and infants younger than 12 months were

76 oid hormones for 285 pregnant women in their third trimester, and also measured cord serum thyroid ho

77 ained during the first trimester, during the third trimester, and at delivery.

78 an-American and Dominican women during their third trimester, and from their children at ages 3 and 5

79 Energy intake decreased in the third trimester, and most women did not meet the nationa

80 hocardiograms in the first trimester, in the third trimester, and postpartum.

81 .5 in the first trimester, second trimester, third trimester, and whole pregnancy were 1.07 (95% conf

82 acental resistance indices in the second and third trimesters are associated with increased risks of

83 ous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SG

84 f universal ultrasonic fetal biometry in the third trimester as a screening test for small-for-gestat

85 clinically indicated ultrasonography in the third trimester as per routine clinical care and these r

86 Second and third trimester average and maximal daily exposure to fi

87 air pollutant exposures (residence-specific third-trimester black carbon or particulate matter with

88 Third-trimester blood TCM concentrations were also assoc

89 e, whereas PE rates, influenced by the steep third trimester BP increase were similar.

90 race/ethnicity, socioeconomic position, and third-trimester BP; and time trend.

91 ) ABCB1, TLR-3, and TLR-4 mRNA levels in the third trimester but not first trimester.

92 eased prenatal PAH exposure (measured in the third trimester but thought to index exposure for all of

93 h maternal thyroid hormones in the second or third trimesters, but evidence for an association in the

94 fadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-eff

95 restricted invariant NKT (iNKT) cells in the third trimester by administration of alpha-galactosylcer

96 hazard ratios for tertiary amine use in the third trimester by increasing tertiles of nitrite intake

97 We report for the first time that ex-utero third trimester cerebellar metabolite concentrations are

98 hout pregnancy in the placenta as well as in third-trimester chorioamniotic membranes.

99 n decrease in exposure to raltegravir during third trimester compared to postpartum is not considered

100 greater prevalence compared with that in the third trimester.ConclusionThis study identified higher r

101 Plasma samples from mothers during the third trimester, cord blood, breast milk collected 2 mon

102 density lipoprotein cholesterol level during third trimester could be considered as indicators of a h

103 trimester of pregnancy and lowest during the third trimester; CT pulmonary angiography was avoided in

104 exposures in a logistic mixed model, and the third-trimester cumulative exposures in a discrete time

105 D4(+) and CD8(+) T cells obtained from human third trimester decidua and demonstrated that decidual C

106 nnectivity mediated the relationship between third trimester depressive symptoms and child externaliz

107 iated with gestational hyperglycaemia in the third trimester disrupt regulatory element activity and

108 s for neurons and astrocytes, resembling the third trimester embryonic human neocortex.

109 In the third trimester expectant mothers wore personal air samp

110 No association was found between second- or third-trimester exposure to intranasal triamcinolone and

111 ll size for gestational age after second- or third-trimester exposure, 13,284 (6642 exposed) were inc

112 n 641 of 6642 infants (9.7%) with second- or third-trimester exposure, compared with 657 of 6642 unex

113 posure was divided into first-, second-, and third-trimester exposure.

114 ith a 60% increased risk for ASD, higher for third-trimester exposures (OR = 2.0; 95% CI: 1.1, 3.6),

115 Second- and third-trimester exposures increased the odds of bilatera

116 creening of nulliparous women with universal third trimester fetal biometry roughly tripled detection

117 184 fetuses from 2 LQT1 founder populations, third trimester fetal heart rate discriminated between f

118 We investigate third trimester fetal heart rate, routinely recorded wit

119 ns in the lower quartiles had offspring with third-trimester fetal growth restriction, leading to a s

120 Higher third trimester feto-placental vascular resistance, but

121 rum samples were collected during second and third trimesters for evaluation on fasting lipids levels

122 spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) new

123 influence of second-trimester (GW 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular

124 omen who were reportedly infected during the third trimester had given birth, and no infants with app

125 antiviral therapy for pregnant women in the third trimester has been shown to be highly effective in

126 d, with changes in the microbiome during the third trimester having metabolic consequences for the mo

127 ; and hemoglobin decline over the second and third trimesters (hazard ratio, 1.7; confidence interval

128 al first- (sphingomyelin C18:1 and urea) and third-trimester (hexose and citrate) metabolite screenin

129 = 0.622, 95% CI 0.458-0.848, P = 0.002), and third-trimester high-density lipoprotein cholesterol and

130 ure during postnatal days (PND) 2-6 in rats (third trimester human equivalent) leads to long-term dis

131 ates reached 80% vs 55% following second- vs third-trimester immunization (adjusted odds ratio, 3.7 [

132 ti-FHA GMCs were higher following second- vs third-trimester immunization (PT: 57.1 EU/mL [95% confid

133 The adjusted GMC ratios after second- vs third-trimester immunization differed significantly (PT:

134 Maternal immunization during the third trimester, immunization of other infant contacts,

135 tal day 7 (P7), which is comparable with the third trimester in human pregnancy, induces synaptic dys

136 n both ethnic groups, the lower BP up to the third trimester in Pakistani women resulted in a lower G

137 urine samples collected during the first and third trimesters in pregnant women participating in the

138 euptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, e

139 Administration of alpha-GalCer in the third trimester induced an increase in the activation of

140 This effect was only observed in third-trimester infection.

141 6], with the lowest rate reported during the third trimester (IRR, 0.47; 95% CI, 0.35-0.64) for all a

142 Compared with the third trimester, lamotrigine serum concentration increas

143 rent wheezing through 3 years of age and (2) third trimester maternal 25-hydroxyvitamin D levels.

144 Third trimester maternal Edinburgh Postnatal Depression

145 her previously observed associations between third trimester maternal lipid profile and birthweight o

146 nine (nicotine metabolite) were assayed from third trimester maternal sera.

147 ders, hemolytic disease, multiple gestation, third-trimester maternal infection, chorioamnionitis, to

148 1959-1965; exposure levels were measured in third-trimester maternal serum that was collected before

149 ed PFOA and four long-chain PFCAs (ng/mL) in third-trimester maternal serum; infant weight (kg), leng

150 sured phthalate metabolite concentrations in third-trimester maternal urine in a cohort of women enro

151 study demonstrates that second- rather than third-trimester maternal vaccination results in higher b

152 hree years old, or pregnant women during the third trimester, may adversely affect brain development.

153 A cohort of pregnant women in their early third trimester (n = 81) were prospectively enrolled for

154 pressure and ECG were obtained in pregnant (third trimester, n = 18) and non-pregnant (n = 18) women

155 of miniature pigs (second trimester, n = 2; third trimester, n = 2).

156 , to our knowledge, comprehensive data about third-trimester natalizumab exposure are scant.

157 Severe flares in the second and third trimesters occurred in 2.5% and 3.0%, respectively

158 pertussis (Tdap) vaccine at the start of the third trimester of each pregnancy to optimize transplace

159 ily feed by mouth at the equivalent age of a third trimester of gestation as the majority of their te

160 Placental triglyceride oscillations in the third trimester of human pregnancy are lost in large-for

161 he neonatal period that is equivalent to the third trimester of human pregnancy, are potential treatm

162 rkers in plasma or urine from women in their third trimester of pregnancy (n = 200).

163 wo-thirds in the rate of relapses during the third trimester of pregnancy and a significant increase

164 on was stronger when BPA was measured in the third trimester of pregnancy and decreased with time bet

165 D-deficient diet for female mice during the third trimester of pregnancy and lactation.

166 of the cerebral cortex would continue in the third trimester of pregnancy and that preterm birth woul

167 wore a wrist actigraph for 7 days during the third trimester of pregnancy and within three months pos

168 itamin D levels of 30 ng/mL or higher by the third trimester of pregnancy compared with 133 of 391 (3

169 he use of 2800 IU/d of vitamin D3 during the third trimester of pregnancy compared with 400 IU/d did

170 as measured in spot urine samples during the third trimester of pregnancy from 407 African-American a

171 Here we show that the fetus in the third trimester of pregnancy is more likely to engage wi

172 nal infection with the Zika virus during the third trimester of pregnancy is not linked to structural

173 nal infection with the Zika virus during the third trimester of pregnancy is not linked to structural

174 uals with ileal Crohn's disease and in their third trimester of pregnancy often resembled infants fro

175 Supplementation with n-3 LCPUFA in the third trimester of pregnancy reduced the absolute risk o

176 m mother-infant pairs in Bangladesh from the third trimester of pregnancy to 72 weeks postpartum and

177 VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence i

178 Antibiotic use in the third trimester of pregnancy was associated with a small

179 trol analysis, the use of antibiotics in the third trimester of pregnancy was associated with an incr

180 Prenatal exposure to NO2 in the third trimester of pregnancy was associated with higher

181 Rashes in the third trimester of pregnancy were associated with brain

182 al vaccine given in the late second or early third trimester of pregnancy would prevent most maternal

183 of viability for preterm birth encompass the third trimester of pregnancy, a "precritical period" of

184 e enrolled women who were in their second or third trimester of pregnancy, aged at least 15 years, an

185 , a worker carried out one home visit in the third trimester of pregnancy, monthly visits to children

186 omly assigned to receive fish oil during the third trimester of pregnancy, olive oil, or no oil in th

187 In the third trimester of pregnancy, the human fetus has the ca

188 o were treated with natalizumab during their third trimester of pregnancy, we assessed the clinical a

189 que to pregnancy and primarily occurs in the third trimester of pregnancy, with a hallmark of elevate

190 t underwent fetal MRI during their second or third trimester of pregnancy.

191 8%) control mothers received Tdap during the third trimester of pregnancy.

192 e studies carried out in 68 women during the third trimester of pregnancy.

193 ss whether administered during the second or third trimester of pregnancy.

194 that IPT can be safely used in the second or third trimester of pregnancy.

195 llular pertussis vaccine were boosted in the third trimester of pregnancy.

196 al changes in the auditory system during the third trimester of pregnancy.

197 ) were observed four times in the second and third trimester of pregnancy.

198 in the second trimester and to 51.2% in the third trimester of pregnancy.

199 that IPT can be safely used in the second or third trimester of pregnancy.

200 the target concentration (0.04 mg/L) in the third trimester of pregnancy.

201 natal Depression Scale during the second and third trimesters of pregnancy and 3 months postpartum.

202 h 4400 IU/d vitamin D3 during the second and third trimesters of pregnancy by using a subset of cord

203 ency questionnaire in the first, second, and third trimesters of pregnancy was 25%, 11%, and 10%, res

204 t women in 2007-2013 during their second and third trimesters of pregnancy who participated in the MA

205 ldhood growth was measured during second and third trimesters of pregnancy, at birth, and at 6, 12, 2

206 requency questionnaires during the first and third trimesters of pregnancy.

207 ed across the placenta during the second and third trimesters of pregnancy.

208 nal connectome are present in the second and third trimesters of pregnancy.

209 al to reconstruct exposure in the second and third trimesters of prenatal development and during earl

210 ie, not mediated by malaria in the second or third trimester) of malaria in the first trimester on ma

211 muscle weakness resulted in death during the third trimester or shortly after birth.

212 cond trimester OR, 0.5; 95% CI, 0.2-1.2; and third trimester OR, 0.3; 95% CI, 0.1-1.2).

213 d PM2.5 was stronger for exposure during the third trimester (OR = 1.42 per IQR increase in PM2.5; 95

214 d trimester (OR = 1.67; 95% CI: 1.35, 2.08), third trimester (OR = 1.53; 95% CI: 1.24, 1.90), and who

215 0 (95% CI 0-11.95) after an infection in the third trimester (P < .0001).

216 those starting during the first, second, or third trimester (P < .001).

217 mRNA expression increased from the first to third trimester (P < 0.01), and the receptors localized

218 iabetes, preeclampsia/eclampsia or be in the third trimester (P <= 0.01).

219 e monitoring (22.2%) were more common in the third trimester (P = .001).

220 here was high variability between second and third trimester phthalate metabolite concentrations (int

221 aternal characteristics affected second- and third-trimester placental resistance indices.

222 TTP presented primarily in the third trimester/postpartum, but fetal loss was highest i

223 nset hypertension and proteinuria during the third trimester, preeclampsia can progress rapidly to se

224 Third-trimester pregnant women (>/=28 weeks' gestation)

225 PTH and 25(OH)D3 half-life were measured in third-trimester pregnant women (n22) and repeated during

226 g/d) plus natural food folate (400 mug/d) in third-trimester pregnant women, lactating women 5-15 wk

227 cine or placebo were evaluated in 50 healthy third-trimester pregnant women.

228 al heart rate, genotype, and phenotype; mean third trimester prelabor fetal heart rates obtained from

229 Primary outcomes were third-trimester preterm birth (27-36 weeks), birth weigh

230 with younger age, ART initiation during the third trimester, previous defaulting on ART, and postpar

231 l age (PMA) and brain injury during ex-utero third trimester prior to term equivalent age (TEA).

232 he state unemployment rate during the second/third trimester reduced the probability of preterm birth

233 was 2.7 kg and 8.0 kg in the second and the third trimester, respectively, for an average 37-wk GWG

234 g) is 6.7 and 21.7 g/d in the second and the third trimester, respectively.

235 AR of 8.2 and 18.9 g/d in the second and the third trimester, respectively.

236 ary infection in the first and second or the third trimester, respectively.

237 , was 9.1 and 21.2 g/d in the second and the third trimester, respectively.

238 and 27.5% +/- 3.5% in the first, second, and third trimesters, respectively).

239 21%, 19%, and 29% in the first, second, and third trimesters, respectively, with high rates for the

240 ctomy were encountered in the second and the third trimesters, respectively.

241 (33.3% vs. 14.3% and 10.5% in the second and third trimesters, respectively; P = 0.002).

242 with lower fetal length and weight growth in third trimester resulting in a smaller size at birth amo

243 First trimester sCD14 and LBP levels and third trimester sCD14 levels were significantly higher i

244 onachlor and oxychlordane levels measured in third-trimester serum from the mothers of 217 sons with

245 During the second and third trimesters, simultaneously enhanced estrogen level

246 en with parasitemia only detected before the third trimester still had an increased risk of placental

247 An estimated 2.6 million third trimester stillbirths occurred in 2015 (uncertaint

248 Administration of alpha-GalCer in the third trimester suppressed PPARgamma activation, as show

249 t on viral suppression when initiated in the third trimester (T3).

250 binding protein-associated factor (TBP)] and third-trimester [Testis-expressed sequence 15 protein (T

251 However, in the third trimester the PPS was larger than the controls' PP

252 At third trimester, the high TCS concentration was associat

253 During the third trimester, the human brain undergoes rapid cellula

254 stational weight gain strata, especially the third-trimester, the effect of high-density lipoprotein

255 during preconception; the first, second, and third trimesters; the entire period of pregnancy; and F2

256 p study and laboratory evaluation during the third trimester, their offspring underwent a 3-year grow

257 centrations are suppressed in the second and third trimesters, thereby facilitating an increased supp

258 entually leading in the late second or early third trimester to an intense and acutely aggravating sy

259 axis is offered for 4 months starting in the third trimester to women with DNA load >/=10(6) copies/m

260 ed on human placentae from first, second and third trimesters to determine methylation patterns of ho

261 After adjustments for confounders, third-trimester total cholesterol levels were associated

262 (clinical EC90) in 9/28 (32%) mothers in the third trimester, transfer across the placenta (121% of p

263 Despite low plasma DTG exposures in the third trimester, transfer across the placenta and throug

264 ndetected in control or Dex-treated cultured third-trimester trophoblasts.

265 Higher third trimester umbilical and uterine artery vascular re

266 Higher third trimester umbilical artery vascular resistance, bu

267 Third-trimester urinary biomarkers of oxidative/nitrativ

268 , 95% CI=0.40-1.77), or first-, second-, and third-trimester use (odds ratio=1.06, 95% CI=0.71-1.58).

269 , 95% CI=0.37-2.17), or first-, second-, and third-trimester use (odds ratio=1.27, 95% CI=0.82-1.99).

270 In the early third trimester, uterine blood flow was measured by Dopp

271 Results were similar for second and third-trimester vaccination and for analyses considering

272 The geometric mean ratios for third-trimester versus postpartum maraviroc were 0.72 (9

273 Geometric mean ratios of third trimester vs postpartum were 0.55 (90% confidence

274 Mean temperature increase in the third trimester was 0.38 degrees C +/- 0.27, with no sig

275 10-ppb increase in ozone exposure during the third trimester was also associated with a slightly elev

276 For PM(10) from all sources, the third trimester was associated with lower FVC% predicted

277 of antidepressants during the second and/or third trimester was associated with the risk of ASD (31

278 ernal influenza vaccination in the second or third trimester was not associated with increased ASD ri

279 reuptake inhibitors during the second and/or third trimester was significantly associated with an inc

280 weight gain (n=8, 15%) during the second and third trimesters was achieved when energy intake was 125

281 fatty acid composition during the second and third trimesters was significantly associated with SCH i

282 to PM2.5 during pregnancy, particularly the third trimester, was associated with greater odds of a c

283 ent of this possibility, greater second- and third-trimester weight gain beyond a threshold may be pr

284 igher mean PM2.5 and BC exposures during the third trimester were associated with higher SBP (e.g., 1

285 pplications just before conception or during third trimester were at greater risk for both ASD and DD

286 Similarly, children exposed in the second or third trimester were not more likely to be hospitalized

287 r intake (C12h) plasma concentrations in the third trimester were on average 29% and 36% lower, respe

288 mothers vaccinated at the beginning of their third trimester were protected.

289 Pregnant women in their third trimester were screened for eligibility either dur

290 ic, 54% of pregnant women in their second or third trimester were vaccinated.

291 ients for correlation between the second and third trimesters were 0.50 and 0.32 for uterine artery r

292 Placental explants from first and third trimesters were challenged with 0.1 to 10 mug/mL L

293 ecommended weight gain during the second and third trimesters were not increased as compared to energ

294 t women for a GWG of 12 kg in the second and third trimesters were similar to the recalculated 2007 W

295 were found for any trimester, including the third trimester, which is thought to be most relevant (T

296 otal of 3428 pregnant women in the second or third trimester who had falciparum malaria (at any paras

297 changes in dietary intake from the second to third trimester with emphasis on energy intake and carbo

298 ET/MR imaging), and 1 was scanned during the third trimester (with PET).

299 O2) during the first, second, and cumulative third trimesters within 300 m of maternal address were e

300 e number of cigarettes between the first and third trimester, without quitting, still had a higher ri